Published online before print January 18, 2007, doi: 10.1161/01.RES.0000257912.78915.af
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 American Heart Association, Inc.
Clinical Research |
Age-Dependent Impairment of Endothelial Progenitor Cells Is Corrected by Growth Hormone Mediated Increase of Insulin-Like Growth Factor-1
From the Universität Würzburg, Medizinische Klinik I (Kardiologie) (T.T, S.H., S.F., P.G., M.J. G.E., J. Bauersachs), Würzburg, Germany; National Heart and Lung Institute, Imperial College London, Faculty of Medicine (T.T., S.D.A., P.A.P.-W.), London, United Kingdom; Medizinische Hochschule Hannover, Institut für Klinische Pharmakologie (I.K., D.O.S., D.T.), Hannover, Germany; Fraunhofer Institut für Toxikologie und Experimentelle Medizin (ITEM) (T.T., J. Borlak), Hannover, Germany.
Correspondence to Thomas Thum, MD, Universitätsklinikum, Medizinische Klinik I, Kardiologie, Josef-Schneider-Str. 2, 97080 Würzburg, Germany. E-mail Thum_T{at}klinik.uni-wuerzburg.de or Johann Bauersachs, MD, Universitätsklinikum, Medizinische Klinik I, Kardiologie, Josef-Schneider-Str. 2, 97080 Würzburg, Germany. E-mail Bauersachs_J@medizin.uni-wuerzburg.de
Aging is associated with an increased risk for atherosclerosis. A possible cause is low numbers and dysfunction of endothelial progenitor cells (EPC) which insufficiently repair damaged vascular walls. We hypothesized that decreased levels of insulin-like growth factor-1 (IGF-1) during age contribute to dysfunctional EPC. We measured the effect of growth hormone (GH), which increases endogenous IGF-1 levels, on EPC in mice and human subjects. We compared EPC number and function in healthy middle-aged male volunteers (57.4±1.4 years) before and after a 10 day treatment with recombinant GH (0.4 mg/d) with that of younger and elderly male subjects (27.5±0.9 and 74.1±0.9 years). Middle-aged and elderly subjects had lower circulating CD133+/VEGFR-2+ EPC with impaired function and increased senescence. GH treatment in middle-aged subjects elevated IGF-1 levels (126.0±7.2 ng/mL versus 241.1±13.8 ng/mL; P<0.0001), increased circulating EPC with improved colony forming and migratory capacity, enhanced incorporation into tube-like structures, and augmented endothelial nitric oxide synthase expression in EPC comparable to that of the younger group. EPC senescence was attenuated, whereas telomerase activity was increased after GH treatment. Treatment of aged mice with GH (7 days) or IGF-1 increased IGF-1 and EPC levels and improved EPC function, whereas a two day GH treatment did not alter IGF-1 or EPC levels. Ex vivo treatment of EPC from elderly individuals with IGF-1 improved function and attenuated cellular senescence. IGF-1 stimulated EPC differentiation, migratory capacity and the ability to incorporate into forming vascular networks in vitro via the IGF-1 receptor. IGF-1 increased telomerase activity, endothelial nitric oxide synthase expression, phosphorylation and activity in EPC in a phosphoinositide-3-kinase/Akt dependent manner. Small interference RNA-mediated knockdown of endothelial nitric oxide synthase in EPC abolished the IGF-1 effects. Growth hormone-mediated increase in IGF-1 reverses age-related EPC dysfunction and may be a novel therapeutic strategy against vascular disorders with impairment of EPC.
Key Words: endothelial progenitor cells • aging • insulin-like-growth-factor-1 • growth hormone
This article has been cited by other articles:
 |
|
 |
|
  C. Clapp, S. Thebault, M. C. Jeziorski, and G. Martinez De La Escalera Peptide Hormone Regulation of Angiogenesis Physiol Rev, October 1, 2009; 89(4): 1177 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S-T Lee, K. Chu, K-H Jung, H-K Park, D-H Kim, J-J Bahn, J-H Kim, M-J Oh, S. K. Lee, M. Kim, et al. Reduced circulating angiogenic cells in Alzheimer disease Neurology, May 26, 2009; 72(21): 1858 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Leone, M. Valgimigli, M. B. Giannico, V. Zaccone, M. Perfetti, D. D'Amario, A. G. Rebuzzi, and F. Crea From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells Eur. Heart J., April 2, 2009; 30(8): 890 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Brunet-Dunand, C. Vouyovitch, S. Araneda, V. Pandey, L. J.-P. Vidal, C. Print, H. C. Mertani, P. E. Lobie, and J. K. Perry Autocrine Human Growth Hormone Promotes Tumor Angiogenesis in Mammary Carcinoma Endocrinology, March 1, 2009; 150(3): 1341 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-S. Maeng, H.-J. Choi, J.-Y. Kwon, Y.-W. Park, K.-S. Choi, J.-K. Min, Y.-H. Kim, P.-G. Suh, K.-S. Kang, M.-H. Won, et al. Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLC{beta}2 axis Blood, January 1, 2009; 113(1): 233 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Csiszar, N. Labinskyy, V. Perez, F. A. Recchia, A. Podlutsky, P. Mukhopadhyay, G. Losonczy, P. Pacher, S. N. Austad, A. Bartke, et al. Endothelial function and vascular oxidative stress in long-lived GH/IGF-deficient Ames dwarf mice Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H1882 - H1894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Werner, M. Hanhoun, T. Widmann, A. Kazakov, A. Semenov, J. Poss, J. Bauersachs, T. Thum, M. Pfreundschuh, P. Muller, et al. Effects of Physical Exercise on Myocardial Telomere-Regulating Proteins, Survival Pathways, and Apoptosis J. Am. Coll. Cardiol., August 5, 2008; 52(6): 470 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Thum and J. Borlak LOX-1 Receptor Blockade Abrogates oxLDL-induced Oxidative DNA Damage and Prevents Activation of the Transcriptional Repressor Oct-1 in Human Coronary Arterial Endothelium J. Biol. Chem., July 11, 2008; 283(28): 19456 - 19464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Brugts, A. W. van den Beld, L. J. Hofland, K. van der Wansem, P. M. van Koetsveld, J. Frystyk, S. W. J. Lamberts, and J. A. M. J. L. Janssen Low Circulating Insulin-Like Growth Factor I Bioactivity in Elderly Men Is Associated with Increased Mortality J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2515 - 2522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dimmeler and A. Leri Aging and Disease as Modifiers of Efficacy of Cell Therapy Circ. Res., June 6, 2008; 102(11): 1319 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schmitt and L. G. Cantley The impact of aging on kidney repair Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1265 - F1272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Garcia-Fernandez, G. Delgado, J. E. Puche, S. Gonzalez-Baron, and I. Castilla Cortazar Low Doses of Insulin-Like Growth Factor I Improve Insulin Resistance, Lipid Metabolism, and Oxidative Damage in Aging Rats Endocrinology, May 1, 2008; 149(5): 2433 - 2442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Fadini, S. de Kreutzenberg, M. Albiero, A. Coracina, E. Pagnin, I. Baesso, A. Cignarella, C. Bolego, M. Plebani, G. B. Nardelli, et al. Gender Differences in Endothelial Progenitor Cells and Cardiovascular Risk Profile: The Role of Female Estrogens Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 997 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. -T. Lee, K. Chu, K. -H. Jung, D. -H. Kim, E. -H. Kim, V. N. Choe, J. -H. Kim, W. -S. Im, L. Kang, J. -E. Park, et al. Decreased number and function of endothelial progenitor cells in patients with migraine Neurology, April 22, 2008; 70(17): 1510 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Thum and J. Bauersachs Letter by Thum et al Regarding Article, "Oxidant Stress Impairs In Vivo Reendothelialization Capacity of Endothelial Progenitor Cells From Patients With Type 2 Diabetes Mellitus: Restoration by the Peroxisome Proliferator- Activated Receptor-{gamma} Agonist Rosiglitazone" Circulation, March 11, 2008; 117(10): e185 - e185. [Full Text] [PDF]
|
|
|
|
|
|
S. Sukhanov, Y. Higashi, S.-Y. Shai, C. Vaughn, J. Mohler, Y. Li, Y.-H. Song, J. Titterington, and P. Delafontaine IGF-1 Reduces Inflammatory Responses, Suppresses Oxidative Stress, and Decreases Atherosclerosis Progression in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2684 - 2690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Thum, F. Fleissner, I. Klink, D. Tsikas, M. Jakob, J. Bauersachs, and D. O. Stichtenoth Growth Hormone Treatment Improves Markers of Systemic Nitric Oxide Bioavailability via Insulin-Like Growth Factor-I J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4172 - 4179. [Abstract] [Full Text] [PDF]
|
|